| Autor: |
Ali M. Agha, Clarence Gill, Dinu Valentin Balanescu, Teodora Donisan, Nicolas Palaskas, Juan Lopez-Mattei, Saamir Hassan, Peter Y. Kim, Konstantinos Charitakis, Mehmet Cilingiroglu, Thein Hlaing Oo, Michael Kroll, Jean Bernard Durand, Cheryl Hirsch-Ginsberg, Konstantinos Marmagkiolis, Cezar Iliescu |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Frontiers in Cardiovascular Medicine, Vol 7 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2297-055X |
| DOI: |
10.3389/fcvm.2020.00009 |
| Popis: |
Objectives: To evaluate the role of platelet count and thromboelastogram (TEG) in the treatment of thrombocytopenic cancer patients with suspected coronary artery disease (CAD).Background: Cancer patients with CAD and thrombocytopenia are often treated non-invasively (i.e., without coronary angiography when clinically indicated) due to perceived high risk of bleeding. We sought to evaluate coagulability based on TEG and determine if platelet count and TEG could predict bleeding risk/mortality among cancer patients undergoing coronary angiography (CA).Methods: Baseline demographics, platelet count, and TEG parameters were recorded among cancer patients that underwent CA and had a concomitant TEG. Logistic regression and univariate proportional hazards regression analysis were performed to determine the impact of platelet count and coagulability on 24-month overall survival (OS).Results: All patients with platelet count 50,000/mm3 groups, as well as the improved survival, suggest that with appropriate clinical indication and risk/benefit assessment, a cut-off of 50,000/mm3 platelets can be considered for CA in cancer patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
